NUBIYOTA
Nubiyota LLC is a privately held company in Teaneck, NJ and is a Single Location business. Categorized under Biological Products Manufacturers.Their records show it was established in 2013 and incorporated in New Jersey. Current estimates show this company has an annual revenue of 85071 and employs a staff of approximately 1.
NUBIYOTA
Industry:
Biotechnology Manufacturing Pharmaceutical Therapeutics
Founded:
2013-01-01
Address:
Teaneck, New Jersey, United States
Country:
United States
Website Url:
http://www.nubiyota.com
Status:
Active
Contact:
: (917) 626-3566
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network Google Universal Analytics Font Awesome
Similar Organizations
Diversitec
Diversitec is a privately held company.
RBio
RBio is an adult stem cell technology.
Current Employees Featured
Founder
Official Site Inspections
http://www.nubiyota.com Semrush global rank: 7.32 M Semrush visits lastest month: 522
- Host name: 230.233.71.198.host.secureserver.net
- IP address: 198.71.233.230
- Location: Scottsdale United States
- Latitude: 33.6013
- Longitude: -111.8867
- Metro Code: 753
- Timezone: America/Phoenix
- Postal: 85260
More informations about "NuBiyota"
Nubiyota. Better Ecosystem. Better Health.
NuBiyota is a microbiome therapeutics company focused on the development of novel microbiota-based drugs to restore crucial gut equilibrium. An imbalance in this crucial ecosystem is …See details»
Nubiyota - Better Ecosystem. Better Health. About The …
Established in 2013, NuBiyota is a pioneer in next-generation microbiome drug development. NuBiyota holds an exclusive license to the groundbreaking research developed at the University of Guelph, and led by co-founder, Dr. …See details»
NuBiyota - Crunchbase Company Profile & Funding
Nubiyota LLC is a privately held company in Teaneck, NJ and is a Single Location business. Categorized under Biological Products Manufacturers.Their records show it was established in 2013 and incorporated in New Jersey.See details»
NuBiyota - LinkedIn
NuBiyota is a microbiome therapeutics company focused on the development of novel microbiota-based drugs to restore crucial gut equilibrium. An imbalance in this crucial ecosystem is...See details»
Careers at Nubiyota - Join Our Team
NuBiyota’s team comprises dedicated scientists with a thirst for innovation and R&D experience. We are expanding our team in Ontario and New York.See details»
Organization | NuBiyota - Purdue University
Organization Overview. First Clinical Trial. 2016 NCT02865616. First Marketed Drug. None First NDA Approval. None Last Known Activity. 2023 Timeline < Back; View all... NOW. Now; Active …See details»
NuBiyota - VentureRadar
Website: https://www.nubiyota.com/ NuBiyota is a privately-held company developing an innovative microbiome therapeutics platform. NuBiyota has struck a collaborative deal with …See details»
First microbiome-based drug clears phase III, in clinical …
Sep 11, 2020 · NuBiyota and its partner Takeda have a 40-microbe defined consortia drug in a phase I CDI trial. Colitis and cancerSee details»
Yining Zhao - Co-Founder and China CEO @ NuBiyota
Yining Zhao is the current Co-Founder and China CEO of NuBiyota. He previously worked at Lilly Asia Ventures Lilly Asia Fund as a Venture Partner. Yining Zhao attended MIT Sloan School of Management.See details»
Takeda, NuBiyota Partner on Oral Microbiome Therapeutics for ...
Apr 11, 2017 · Takeda Pharmaceutical Company and NuBiyota are partnering to exploit the latter's Microbial Ecosystem Therapeutic platform for developing therapeutic oral microbial …See details»
Contact NuBiyota. Better Ecosystem. Better Health.
NuBiyota develops Microbial Ecosystem Therapeutic products for gastroenterology (GI) indications. Contact us for more informationSee details»
Fecal microbiota potentiate checkpoint inhibitors, unleash
Apr 16, 2021 · At least eight microbiome companies have launched first-in-human trials pairing their microbiome agents with approved immunotherapies (Table 1) to satisfy the growing need …See details»
Takeda Enters Into Strategic Collaboration With NuBiyota For
Apr 11, 2017 · OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited today announced a strategic collaboration with NuBiyota LLC for the development of Microbial …See details»
Takeda Enters into Strategic Collaboration with NuBiyota for …
Takeda and NuBiyota will collaborate to advance oral microbial consortia products developed by using NuBiyota’s microbiome platform for GI indications. NuBiyota will receive an upfront …See details»
Nubiyota Technology - Microbial Ecosystem Therapeutics
NuBiyota’s Microbial Ecosystem Therapeutics (MET) technology utilizes the microbiota derived from an individual “super donor”. This microbiota demonstrated efficacy across several …See details»
The Safety and Efficacy of Microbial Ecosystem Therapeutic-2 in …
Sep 22, 2021 · All monitoring visits will be conducted by PhaseAdvance, a contract research organization appointed by NuBiyota LLC, to ensure compliance with the ICH guidelines for …See details»
Takeda Enters into Strategic Collaboration with NuBiyota for …
Apr 11, 2017 · Takeda and NuBiyota will collaborate to advance oral microbial consortia products developed by using NuBiyota’s microbiome platform for GI indications.See details»
Publications - Nubiyota
Oct 1, 2016 · NuBiyota’s Microbial Ecosystem Therapeutics platform technology has been confirmed in numerous publications. The effect of microbial ecosystem therapeutic (MET-2) on …See details»
MET-3 - Drug Targets, Indications, Patents - Synapse
MET-3: a Bacteria replacements, Microbiome modulators Drug, Initially developed by Nubiyota LLC, Now, its global highest R&D status is Phase 2, Mechanism: Bacteria …See details»
Nubiyota Pipeline – Better Ecosystem. Better Health.
NuBiyota is developing a pipeline of multi-strain microbiome therapeutic composition candidates to treat a range of medical conditions and diseases, using its proprietary Microbial Ecosystem …See details»